



# New Hampshire Health Alert Network

## Health.Alert@nh.gov

**Message Type:** Alert  
**Status:** Actual  
**Severity:** Moderate  
**Sensitive:** Not Sensitive  
**Message Identifier:** HAN #20100629 Mosquito-borne Disease in NH Update  
**Delivery Time:** 12 hours  
**Acknowledgement:** No  
**Originating Agency:** NH Department of Health and Human Services, Division of Public Health Services

---

**DATE:** Tuesday, June 29, 2010

**TIME:** 1000 EDT

**TO:** Physicians, Infection Control Practitioners, Infectious Disease Specialists, Community Health Centers, Hospital Emergency Departments, NHHA, Manchester Health Department, Nashua Health Department, Public Health Network, DHHS Outbreak Team, DPHS Investigation Team, Zoonotic Alert Team, and DPHS Management Team

**FROM:** Jodie Dionne-Odom, MD, Deputy State Epidemiologist

**SUBJECT:** Mosquito-borne Disease in New Hampshire – Update

### **NH Department of Health and Human Services (NH DHHS) recommends:**

- Awareness of mosquito-borne diseases in NH, including Eastern Equine Encephalitis (EEE) and West Nile Virus (WNV).
- Vigilance and prompt treatment for mosquito-borne disease in patients with compatible clinical features.
- Timely reporting of suspect and confirmed cases of mosquito-borne diseases to NH DHHS Communicable Disease Control and Surveillance Section at 603-271-4496 (after hours 800-852-3345 ext. 5300).
- Prevention measures include avoiding mosquito bites by use of protective clothing and insect repellents, and environmental reduction of mosquito populations.
- Equine vaccines for EEE and WNV are available and should be used to protect horses. There are no recommended vaccines for humans.

### **A) Epidemiology**

Arboviruses such as West Nile virus (WNV) and Eastern Equine Encephalitis (EEE) virus are transmitted to humans through the bite of an infected mosquito. The viruses are maintained in a bird-mosquito cycle with humans considered incidental hosts. The seasonality of arboviral transmission is variable and depends on the geographic location of exposure, the specific cycles of viral transmission, and local climatic conditions. The time of highest risk for human infection in NH has been identified between July and October. Year-round transmission is possible in some geographic locations in the U.S., therefore WNV or EEE should be considered in persons with consistent travel history.

Alternate modes of transmission for WNV, such as through blood transfusion and organ transplantation from infected donors, occupational sharps injury exposures, transplacental transmission, and probable transmission via breast milk have been documented.

Nationally, for the 2009 season, there were 720 WNV human cases reported to the Centers for Disease Control and Prevention (CDC). Neuroinvasive Disease (cases of severe disease, specifically meningitis and encephalitis) was apparent in 373 (52%) of these diagnosed cases, 322 (45%) were diagnosed with West Nile fever (milder disease), and 25 (3%) were clinically unspecified. In 2003, NH reported 3 human WNV cases, all survived. Between 1964 and 2009, 261 human cases of EEE were reported in the US, with an average of 6 cases per year. In 2005, NH reported 7 human EEE cases, which included 2 deaths. During 2007, 3 human EEE cases were reported and in 2009, 1 human EEE case was reported.

Approximately 1 in 150 WNV infections will result in severe neurological disease with encephalitis being reported more commonly than meningitis. Approximately one-third of all people with clinical encephalitis caused by EEE virus will die from the disease. Of those who recover, many will suffer permanent brain damage with many of those requiring long-term institutional care. Severe neurological disease due to WNV and EEE virus has occurred in patients of all ages.

### **B) When to Suspect Arboviral Illness**

The incubation period following the bite of an infected mosquito ranges from 3 to 14 days and symptoms may last for several days to months or may even be life-long. Most arboviral infections are mild and often clinically unapparent. Mild forms of arboviral infection are described as a febrile illness of sudden onset often accompanied by headache, myalgias, arthralgias, which is sometimes accompanied by skin rash or lymphadenopathy. Approximately 20% of those infected with WNV develop a mild illness known as West Nile Fever.

Symptoms of arboviral infection occurring among patients hospitalized with severe neurological disease included fever, headache and altered mental status ranging from confusion to coma, with or without additional signs of brain dysfunction. Less common neurological syndromes can include cranial and peripheral neuritis or other neuropathies, including acute flaccid paralysis syndrome. A minority of patients with severe disease develop a maculopapular or morbilliform rash involving the neck, trunk, arms, or legs. Although not observed in recent outbreaks, myocarditis, pancreatitis, and fulminant hepatitis have been described.

Laboratory findings among patients in recent outbreaks included normal or elevated total leukocyte counts, lymphocytopenia and anemia, and hyponatremia in peripheral blood. Examination of cerebrospinal fluid (CSF) showed pleocytosis (usually with a predominance of lymphocytes), elevated protein, and normal glucose levels. For about one-third of WNV patients, magnetic resonance imaging (MRI) showed enhancement of the leptomeninges, the periventricular areas, or both, while MRI of EEE patients often revealed abnormalities of the basal ganglia and thalami.

See attached Submission Guidelines for Arboviral Testing for information on diagnostic testing. Guidelines may also be viewed at: <http://www.dhhs.state.nh.us/DHHS/CDCS/West+Nile+Virus/wnv-hc-info.htm>

Treatment is supportive, often involving hospitalization, intravenous fluids, respiratory support, and prevention of secondary infections for patients with severe disease.

For additional clinical information please refer to:

Deresiewicz, R., Scott, J., Thaler, Hsu, L., Zamani, A. 1997. Clinical and Neuroradiographic Manifestations of Eastern Equine Encephalitis. *The New England Journal of Medicine* 336:1867-1874.

Petersen, L., Marfin. A. 2002. West Nile virus: A Primer for the Clinician. *Annals of Internal Medicine* 137:173-9.

Sejvar, J. 2007. The Long-term Outcomes of Human West Nile virus Infection. *Clinical Infectious Diseases* 44:1617-24.

The Centers for Disease Control, Division of Vector-Borne Infectious Diseases website at:  
<http://www.cdc.gov/ncidod/dvbid/westnile/clinicians/>.

See “The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America” for additional information on the diagnosis and treatment of patients with encephalitis.

<http://www.idsociety.org/content.aspx?id=9088>

### C) When to Report Suspected Cases of Arboviral Illness

Clinicians, hospitals, and laboratories should report **within 24 hours** any patient meeting the following criteria.

1. Any patient with encephalitis or meningitis, who meet criteria a, b and c below:
  - a. Fever  $\geq 38.0$  C or 100 F, and
  - b. CNS involvement including altered mental status (altered level of consciousness, confusion, agitation, lethargy) and/or other evidence of cortical involvement (e.g., focal neurologic findings, seizures), and
  - c. Abnormal CSF profile suggesting a viral etiology (a negative bacterial stain and culture) showing pleocytosis with predominance of lymphocytes. Protein levels are elevated. Glucose levels are normal.
2. Guillain-Barre syndrome, especially with atypical features, such as fever, altered mental status, and/or pleocytosis.

### D) How to Report Suspect Cases of Arboviral Illness

All suspect cases should first be reported to the New Hampshire Department of Health and Human Services (NHDHHS) by telephone. A completed case report form (enclosed) must be faxed to the NH Communicable Disease Control Section (603-271-0545) **and** a copy submitted with the laboratory specimen(s) to the NH Public Health Laboratories. Communicable Disease Control staff is available to help determine if the clinical presentation meets the case criteria for viral meningo-encephalitis and whether further testing would be appropriate. Specimen submission guidelines are enclosed.

### Diagnostic Testing Fee Schedule

TEST	CPT
Eastern Equine Encephalitis (EEE) virus antibodies, IgM	86652
St. Louis Encephalitis (SLE) virus antibodies, IgM	86653
West Nile (WNV) virus antibodies, IgM	86788

- All specimens submitted to the Public Health Laboratories will be screened for EEE, SLE, and WNV.
- The Total Cost Per Screen is \$105.00.

**Note: All spinal fluid submissions must be accompanied by a corresponding serum sample. There will be only a single charge for the paired specimens.**

Please feel free to contact the Communicable Disease Control Section if you have any questions. During business hours (8 am to 4:30 pm), call 603-271-4496 or 1-800-852-2345, extension 4496. Nights or weekends call the New Hampshire Hospital switchboard at 1-800-852-3345, extension 5300 and request the Public Health Professional on-call.

For additional information on arboviral illness, including fact sheets and maps of recent activity, please visit the NHDHHS WNV/EEE website at <http://www.dhhs.state.nh.us/DHHS/CDCS/West+Nile+Virus/default.htm>. A toll free WNV/EEE information line is also available during the summer months. The phone number is 1-866-273-NILE (6453).

**For any questions regarding the contents of this message, please contact NH DHHS Communicable Disease Control and Surveillance Section at 603-271-4496 (after hours 1-800-852-3345 ext.5300).**

**Attachments:** *Submission Guidelines for Arboviral Testing*  
*NH Arboviral Case Report Form*

---

## DEFINITION OF TERMS AND ALERTING VOCABULARY

### **Message Type**

Alert: Indicates an original alert  
Update: Indicates prior alert has been updated and superseded  
Cancel: Indicates prior alert has been cancelled  
Error: Indicates prior alert has been retracted

### **Status**

Actual: Communication or alert refers to a live event  
Exercise: Designated recipients must respond to the communication or alert  
Test: Communication or alert is related to a technical, system test and should be disregarded

### **Severity**

Extreme: Extraordinary threat to life or property  
Severe: Significant threat to life or property  
Moderate: Possible threat to life or property  
Minor: Minimal threat to life or property  
Unknown: Unknown threat to life or property

### **Sensitive**

Sensitive: Indicates the alert contains sensitive content  
Not Sensitive: Indicates non-sensitive content

**Message Identifier:** A unique alert identifier that is generated upon alert activation.

**Delivery Time:** Indicates the timeframe for delivery of the alert.

**Acknowledgement:** Indicates whether an acknowledgement on the part of the recipient is required to confirm that the alert was received, and the timeframe in which a response is required.

**Originating Agency:** A guaranteed unique identifier for the agency originating the alert.

**Alerting Program:** The program sending the alert or engaging in alerts and communications using PHIN Communication and Alerting (PCA) as a vehicle for their delivery.

**You have received this message based upon the information contained within our emergency notification database.**

**If you have a different or additional e-mail or fax address that you would prefer to be used please contact:**

Denise M. Krol, MS  
NH HAN Coordinator  
[Denise.Krol@dhhs.state.nh.us](mailto:Denise.Krol@dhhs.state.nh.us)

**Business Hours 8:00 AM – 4:00 PM**  
Tel: 603-271-4596  
Fax: 603-271-0545